Summary of Significant Accounting Policies - Other (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) customer segment	Dec. 31, 2022 USD ($)
Product Revenue, net
Number of customers | customer	3
Trade Receivables, net
Accounts receivable, net	$ 3,799	$ 6,348
Allowance for doubtful accounts.	$ 0	0
Payment terms	30 days
Segment Information
Number of operating segments | segment	1
Accrued clinical trial expenses	$ 4,700	5,700
Prepaid clinical expenses	5,200	3,900
ZTALMY
Trade Receivables, net
Accounts receivable, net	2,600	$ 1,300
Inventory
Cost of product and materials included in research and development expenses prior to FDA approval	$ 2,000
ZTALMY | Revenue Benchmark | Customer Concentration Risk
Product Revenue, net
Concentration risk, as a percent	99.00%
Number of customers | customer	1